A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on genetic mutations.

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the risk of death compared to the investigator’s choice of chemotherapy in the ...

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March 2025 issue of Lung Cancer by Shahnam et al. KRAS G12D and G12C mutations exh ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.